• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?KEYNOTE-042研究：降低一线帕博利珠单抗单药治疗的PD-L1阈值是个好主意吗？
Transl Lung Cancer Res. 2019 Oct;8(5):723-727. doi: 10.21037/tlcr.2019.05.03.
2
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.帕博利珠单抗单药治疗 PD-L1 阳性晚期非小细胞肺癌老年患者的安全性和有效性：来自 KEYNOTE-010、KEYNOTE-024 和 KEYNOTE-042 研究的汇总分析。
Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8.
3
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.一线帕博利珠单抗单药治疗高龄（≥75 岁）非小细胞肺癌患者的疗效和安全性。
J Cancer Res Clin Oncol. 2020 Feb;146(2):457-466. doi: 10.1007/s00432-019-03072-1. Epub 2019 Dec 18.
4
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.在 KEYNOTE-006 研究中，接受派姆单抗或伊匹单抗治疗的晚期黑色素瘤患者的治疗线和程序性死亡配体 1 表达的结果：一项随机临床试验。
Eur J Cancer. 2018 Sep;101:236-243. doi: 10.1016/j.ejca.2018.06.034. Epub 2018 Aug 7.
5
Pembrolizumab in lung cancer: current evidence and future perspectives.派姆单抗治疗肺癌：当前的证据和未来的前景。
Future Oncol. 2019 Oct;15(29):3327-3336. doi: 10.2217/fon-2019-0073. Epub 2019 Aug 21.
6
First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment.一线帕博利珠单抗单药治疗转移性PD-L1阳性非小细胞肺癌：治疗时间的真实世界分析
Immunotherapy. 2019 Jul;11(10):889-901. doi: 10.2217/imt-2019-0061. Epub 2019 Jun 11.
7
Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland.帕博利珠单抗对比化疗作为 PD-L1 高表达转移性非小细胞肺癌一线治疗药物在瑞士的成本效果分析。
Swiss Med Wkly. 2019 Dec 27;149:w20170. doi: 10.4414/smw.2019.20170. eCollection 2019 Dec 16.
8
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.帕博利珠单抗作为程序性死亡受体配体1（PD-L1）阳性晚期非小细胞肺癌患者的一线治疗：一项1期试验。
Ann Oncol. 2017 Apr 1;28(4):874-881. doi: 10.1093/annonc/mdx008.
9
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.帕博利珠单抗联合化疗对比化疗联合帕博利珠单抗单药一线治疗美国鳞状非小细胞肺癌的成本效果分析。
Curr Med Res Opin. 2019 Jul;35(7):1241-1256. doi: 10.1080/03007995.2019.1571297. Epub 2019 Jan 29.
10
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.帕博利珠单抗联合化疗在美国非鳞状非小细胞肺癌一线治疗中的成本效益
J Med Econ. 2018 Dec;21(12):1191-1205. doi: 10.1080/13696998.2018.1521416. Epub 2018 Sep 21.

引用本文的文献

1
Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments.接受基于免疫疗法治疗的晚期非小细胞肺癌患者外周血生物标志物与临床结局之间的相关性。
Transl Lung Cancer Res. 2021 Dec;10(12):4477-4493. doi: 10.21037/tlcr-21-710.
2
To treat or not to treat: A rare case of response to pembrolizumab-based immunotherapy-chemotherapy in non-small cell lung cancer with acute liver failure due to multiple bile duct metastases.治疗还是不治疗：免疫化疗治疗非小细胞肺癌伴多发胆管转移致急性肝衰竭的罕见疗效病例
Thorac Cancer. 2021 Feb;12(4):553-556. doi: 10.1111/1759-7714.13793. Epub 2020 Dec 27.

本文引用的文献

1
Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.体能状态为2的非小细胞肺癌患者的免疫治疗：证据匮乏情况下的临床决策
J Clin Oncol. 2019 Aug 1;37(22):1863-1867. doi: 10.1200/JCO.18.02118. Epub 2019 Apr 17.
2
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.基于临床基因组数据库的非小细胞肺癌患者的患者特征和肿瘤基因组与临床结局的相关性分析。
JAMA. 2019 Apr 9;321(14):1391-1399. doi: 10.1001/jama.2019.3241.
3
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
4
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.KEYNOTE-024 更新分析：PD-L1 肿瘤比例评分≥50%的晚期非小细胞肺癌的帕博利珠单抗对比铂类化疗
J Clin Oncol. 2019 Mar 1;37(7):537-546. doi: 10.1200/JCO.18.00149. Epub 2019 Jan 8.
5
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
6
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
7
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
8
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.一线纳武利尤单抗用于IV期或复发性非小细胞肺癌
N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.
9
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
10
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.PD-L1 免疫组织化学检测在肺癌中的应用：蓝图 PD-L1 IHC 检测比较项目第一阶段的结果。
J Thorac Oncol. 2017 Feb;12(2):208-222. doi: 10.1016/j.jtho.2016.11.2228. Epub 2016 Nov 29.

KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?

作者信息

Pacheco Jose M

机构信息

Thoracic Oncology Program, Division of Medical Oncology, Department of Internal Medicine, University of Colorado Cancer Center, Aurora, CO, USA.

出版信息

Transl Lung Cancer Res. 2019 Oct;8(5):723-727. doi: 10.21037/tlcr.2019.05.03.

DOI:10.21037/tlcr.2019.05.03
PMID:31737510
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6835104/
Abstract
摘要